Skip to main content

Profile hero

Adam Golden

Partner and Head of US Life Sciences Transactions

Life sciences | Mergers and acquisitions |

Adam is an industry expert and it is always reassuring to have him as part of the team.

Chambers USA 2024

Profile details

About Adam Golden

Adam heads US life sciences transactions. Based in New York, he advises clients on M&A, licenses and collaborations, venture capital financings and commercial transactions in the life sciences sector. A dual M&A and IP transactions lawyer, Adam has deep experience representing pharmaceutical, biotech and medical device companies and investors on a broad range of transactions, including hybrid deals such as M&A transactions with back-end milestone payments, carve-outs, options to acquire or license and product divestitures. He also regularly advises clients on related transition service, manufacturing and supply, and other operational agreements.

Adam is recognized as a leading life sciences practitioner by Chambers Global, Chambers USA, Legal 500 US, Who's Who Legal, Lawdragon, LMG Life Sciences, IFLR1000 and IAM Patent 1000. He has been shortlisted as M&A Attorney of the Year and Life Sciences Star by LMG Life Sciences, and a Life Sciences MVP by Law360.




Recent work

Select M&A Transactions

  • Roivant Sciences on its $7.1 billion sale of Telavant to Roche.
  • Novartis in its acquisition of DTx Pharma, a biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
  • Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc.
  • Moderna on its acquisition of OriCiro Genomics K.K.
  • Rayner Surgical on its acquisition of the product OMIDRIA® from Omeros Corporation in a transaction valued in excess of $1 billion.
  • Ipsen on the sale to Fusion Pharmaceuticals of rights to a radiopharmaceutical developed for oncology indications.
  • Novartis on its acquisition of Cadent Therapeutics, a clinical-stage neuroscience company.
  • Engrail Therapeutics on its acquisition of NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation.
  • Novartis on its acquisition of Vedere Bio, including a platform for AAV-based delivery of gene therapies and an optogenetics program.
  • Altavant Sciences on its acquisition of Onspira Therapeutics, a private drug development company focused on therapeutics for rare pulmonary diseases.
  • Bausch Health on its option to purchase the ophthalmology assets of Allegro Pharmaceuticals.
  • Novartis on its acquisition of IFM Tre for up to $1.6bn and its option to acquire IFM Due for up to $840m.
  • Celgene on its $9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.
  • Novartis on its $8.7bn acquisition of AveXis, a clinical-stage gene therapy biotech company.
  • Celgene on its acquisition of Impact Biomedicines for up to $7bn, a clinical stage company developing fedratinib for myelofibrosis.
  • Chase Pharmaceuticals on its sale to Allergan for up to $1bn.
  • Alcon Laboratories on its acquisitions of Encore Vision, RxSight and Transcend Medical.
  • Bausch Health on the sale of Dendreon Pharmaceuticals to Sanpower.

Select License and Collaboration Transactions

  • AbbVie on its collaboration and option agreement with Parvus Therapeutics to develop and commercialize treatments for IBD, utilizing Parvus’ proprietary NavacimTM platform technology.
  • Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases.
  • SERB Pharmaceuticals in its acquisition of exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
  • Novartis on its global co-development and co-commercialization agreement with UCB for Parkinson’s Disease therapies.
  • Spark Therapeutics on its collaboration and option agreement with Senti Biosciences with respect to the development of next-generation precision gene therapies.
  • Novartis on its exclusive worldwide license and collaboration agreement with Mesoblast Limited to develop remestemcel-L for the treatment of acute respiratory distress syndrome, including that associated with COVID-19.
  • Gilead Sciences on a license agreement with Xencor for the use of XmAB® antibody technologies in investigational agents for HIV.
  • Gilead Sciences on its strategic collaboration with Tango Therapeutics to develop and commercialize innovative targeted immuno-oncology treatments for cancer.
  • Kite, a Gilead company, on an up to $3bn deal to access Sangamo Therapeutics’ zinc finger nuclease technology.
  • Celgene on strategic collaborations with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics and Skyhawk Therapeutics.
  • Gilead Sciences on its $150m collaboration with Agenus to develop and commercialize novel immuno-oncology therapies.
  • Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.
  • Novartis on strategic collaborations with Sangamo Therapeutics, Surface Therapeutics, Xencor and Homology Medicines.



New York University School of Law

  • J.D.

Princeton University

  • A.B.

Bar admissions

  • New York
  • Massachusetts